Skip to search formSkip to main contentSkip to account menu

pertuzumab

Known as: rhuMAb 2C4, Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer, rhuMAb2C4 
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of… 
National Institutes of Health

Related topics

Related topics

10 relations
14 ML pertuzumab 30 MG/ML Injection14 ML pertuzumab 30 MG/ML Injection [Perjeta]2C4 antibodyHER2/Neu/cerbB2 Antagonists [MoA]

Broader (2)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents

Narrower (2)

OmnitargPerjeta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer…
100Background: The NCI-MATCH is the largest national signal-finding trial incorporating centralized genomic testing to direct pts… 
2017
2017
Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
In a Phase III trial for HER2-positive breast cancer (the CLEOPATRA study), the triple-drug combination arm of pertuzumab plus… 
2017
2017
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting
Aim: Resistance to trastuzumab (which is a standard therapy for breast cancer patients with HER2 overexpression) is associated… 
2016
2016
Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.
1022 Background: Pertuzumab binds to the dimerization epitope of the HER2 receptor, inhibits HER dimerization and signal… 
Review
2016
Review
2016
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?
Highly Cited
2013
Highly Cited
2013
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian…
BACKGROUND Pertuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor (HER)-mediated signalling… 
2012
2012
Target Points in Trastuzumab Resistance
Epidermal growth factor (EGF) family of receptors is involved in cell growth and differentiation. The human EGF2 (HER2) lacks… 
2010
2010
Re-epithelialization from human skin explant cultures is promoted by ligand-activated HER3 receptor.
2008
2008
A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive…
5520 Background: Pertuzumab is a monoclonal antibody which specifically binds HER2 and prevents its dimerisation with either… 
Highly Cited
2007
Highly Cited
2007
Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo1
Human epidermal growth factor receptor-2 (HER-2)/neu (ErbB2), a member of the epidermal growth factor family of receptors, is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)